Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Soligenix Inc SNGX

Healthcare Biotechnology
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Recent & Breaking News (NDAQ:SNGX)

Soligenix Announces Accelerated Publication Demonstrating Efficacy and Broad Neutralizing Activity of its COVID-19 Vaccine in Non-Human Primates

PR Newswire September 28, 2021

Soligenix Invited to Present at the Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 27, 2021

Soligenix to Advance Synthetic Hypericin Development in Psoriasis

PR Newswire September 16, 2021

Soligenix Develops Groundbreaking Vaccine Platform to Target Future Pandemics

Newsfile September 14, 2021

FDA Grants Soligenix Orphan Drug Designation for the Treatment of T-cell Lymphoma

PR Newswire September 9, 2021

Soligenix: Developing Tools to Tackle the Next Potential Pandemic; PCG Digital Biotech Watch Review

PR Newswire August 24, 2021

Soligenix Announces Publication Demonstrating Successful Formulation and Heat Stabilization of Filovirus Vaccine Platform for Ebola and Marburg Virus Diseases

PR Newswire August 23, 2021

Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates

PR Newswire August 18, 2021

Soligenix Announces Recent Accomplishments And Second Quarter 2021 Financial Results

PR Newswire August 13, 2021

Who Is Preparing Us for the Next Potential Pandemic?

Newsfile July 29, 2021

HyBryte(TM): Addressing an Unmet Need for Rare Lymphoma

Newsfile July 22, 2021

50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021

Accesswire June 23, 2021

HyBryte(TM) Positive Pivotal Phase 3 FLASH Study Selected for Presentation at the United States Cutaneous Lymphoma Consortium (USCLC) Annual Meeting

PR Newswire June 22, 2021

Soligenix Receives Pediatric Investigational Plan Waiver for HyBryte(TM) in CTCL from the European Medicines Agency

PR Newswire June 10, 2021

Soligenix Receives $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

PR Newswire June 9, 2021

Shining a Light on Soligenix's HyBryte(TM) Growth Opportunity

Newsfile June 3, 2021

Soligenix Receives Japanese Patent for Improved Production of Synthetic Hypericin Composition

PR Newswire May 20, 2021

Soligenix Announces Recent Accomplishments And First Quarter 2021 Financial Results

PR Newswire May 17, 2021

HyBryte(TM) Awarded Innovation Passport in the United Kingdom

PR Newswire May 10, 2021

Soligenix Presents at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research

PR Newswire April 28, 2021